Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory, Fibrotic, and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for KCNN4 (KCa3.1) drug discovery. Because KCNN4 is a complex multi-pass ion channel, preserving its native tetrameric conformation is vital. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KCNN4 Full-Length Membrane Protein Prep or Extracellular Loops (ECL) Antigen High purity (>85-95%), DDM/CHS solubilized. Sequence Verified. |
View KCNN4 Products |
| Gene Delivery | KCNN4 Promise-ORF Lentivirus Premade Particles Full-length ORF for stable cell line construction. HEK293T packaging, Puromycin selection. Essential for calcium flux & patch-clamp. |
View KCNN4 Products |
| Benchmark Ab | Anti-KCNN4 Monoclonal Antibody (Research Grade) Recombinant positive control for Western, Flow & binding assays. Sequence Verified. |
View KCNN4 Products |
| Validator | KCNN4 siRNA Set (3 unique sequences) For knockdown verification. Sequence Verified, >90% knockdown efficiency. |
View KCNN4 Products |
| Related Target A | KCNN1 (SK1) Selectivity screening - Critical off-target for SK channel inhibitors. CNS toxicity avoidance. |
View KCNN1 Products |
| Related Target B | KCNN2 (SK2) Subfamily counter-screening to confirm KCNN4 specificity. |
View KCNN2 Products |
| Related Target C | KCNN3 (SK3) Small-conductance Ca²⁺-activated K⁺ channel for selectivity counter-screening. |
View KCNN3 Products |
| Related Target D | KCNMA1 (BK) Large-conductance Ca²⁺-activated K⁺ channel for broad ion channel selectivity panel. |
View KCNMA1 Products |
| Related Target E | ORAI1 Upstream calcium signaling partner, synergistic target for immune modulation. |
View ORAI1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Functional expression in heterologous cells (Ion channel conformation) | Lentivirus Premade Particles with Puromycin selection. Guaranteed expression in HEK293. Ready for automated patch-clamp. |
| Cross-species cyno/mouse eval (Toxicology bridging) | Human/Mouse/Cyno ortholog lentiviral constructs available. Sequence identity >95%. |
| Selectivity vs SK1/SK2/SK3 subfamily | KCNN1/KCNN2/KCNN3 protein standards available for competitive binding assays. Homolog panel lentivirus strictly sequence verified. |
| False Positives / Specificity control | Validated siRNA included for target specificity verification in functional assays. |
| Native Conformation & Tetramerization | High-titer sequence-verified Lentivirus Premade Particles for stable cell line construction, guaranteeing native expression. |
| Lack of Validated Controls | Clinical Benchmark Antibodies included for FACS and assay calibration. |
Live KCNN4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KCNN4 (KCa3.1) therapeutics is intensifying, with major players shifting focus from hematologic indications toward immune-inflammatory diseases, fibrosis, and oncology. Following the discontinuation of first-generation inhibitors in sickle cell disease (e.g., Senicapoc), the next wave of R&D is targeting high-selectivity small molecules for ulcerative colitis, atopic dermatitis, and idiopathic pulmonary fibrosis (IPF). In parallel, emerging modalities such as monoclonal antibodies targeting extracellular loops (ECL) and peptide therapeutics derived from venom toxins are gaining traction for immuno-oncology and Alzheimer's disease. Key challenges remain: achieving >100-fold selectivity over KCNN1/2/3 to avoid neuro/cardiotoxicity, and developing robust cell-based assays for functional validation. As understanding of KCNN4's role in T-cell activation, macrophage polarization, and cancer metastasis deepens, investment in combination therapies targeting the tumor microenvironment is expected to increase.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Sanofi (historical), Icagen, Senicapoc repurposing, Academic consortia | Sickle Cell (discontinued), IBD, Fibrosis, Alzheimer's | Selectivity Assay (Need KCNN1/2/3 ortholog proteins for counter-screening) |
| siRNA / Gene Therapy | Early-stage biotechs | Autoimmune diseases | Knockdown Validation (Need potent siRNA sets with sequence verification) |
| Monoclonal Antibody | Academic Spin-offs, Emerging Biotech | Solid Tumors, Autoimmune | Binding & FACS (Need sequence-verified ECL antigens) |
| Functional Antibody | Research institutions | Immunology research | Cell Surface Binding (Need lentivirus-stable cell lines for FACS) |
| Peptide Therapeutics | Venom-derived peptide engineers | Immunosuppression | Calcium Flux (Need stable cell lines via high-titer Lentivirus) |